
Company valuation, historical trends, and peer comparisons.
According to Veracyte, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.06B. This represents a change of 22.06% compared to the average of 3.33B of the last 4 quarters.
The mean historical Enterprise Value of Veracyte, Inc. over the last ten years is 1.60B. The current 4.06B Enterprise Value has changed 153.18% with respect to the historical average. Over the past ten years (40 quarters), VCYT's Enterprise Value was at its highest in in the June 2026 quarter at 4.42B. The Enterprise Value was at its lowest in in the March 2018 quarter at 188.65M.
Average
1.60B
Median
1.68B
Minimum
189.45M
Maximum
2.99B
Discovering the peaks and valleys of Veracyte, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 176.63%
Maximum Annual Enterprise Value = 2.99B
Minimum Annual Increase = -41.03%
Minimum Annual Enterprise Value = 189.45M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 2.99B | 5.11% |
| 2024 | 2.84B | 58.28% |
| 2023 | 1.79B | 15.16% |
| 2022 | 1.56B | -41.03% |
| 2021 | 2.64B | 16.50% |
| 2020 | 2.27B | 98.56% |
| 2019 | 1.14B | 176.63% |
| 2018 | 413.00M | 94.00% |
| 2017 | 212.89M | 12.37% |
| 2016 | 189.45M | 24.03% |
The current Enterprise Value of Veracyte, Inc. (VCYT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.54B
5-year avg
2.36B
10-year avg
1.60B
Veracyte, Inc.’s Enterprise Value is greater than Insight Molecular Diagnostics Inc. (71.59M), greater than NeoGenomics, Inc. (756.49M), less than BillionToOne, Inc. (4.95B), greater than Myriad Genetics, Inc. (678.11M), greater than bioAffinity Technologies, Inc. (17.41M), less than Guardant Health, Inc. (23.27B), greater than GeneDx Holdings Corp. (2.17B), greater than Biodesix, Inc. (216.73M), greater than Personalis, Inc. (1.63B), greater than Castle Biosciences, Inc. (1.07B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 71.59M | $86.72M | |
| 756.49M | $2.23B | |
| 4.95B | $5.37B | |
| 678.11M | $575.81M | |
| 17.41M | $18.41M | |
| 23.27B | $22.62B | |
| 2.17B | $2.07B | |
| 216.73M | $174.93M | |
| 1.63B | $1.69B | |
| 1.07B | $1.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Veracyte, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Veracyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Veracyte, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Veracyte, Inc. (VCYT)?
What is the 3-year average Enterprise Value for Veracyte, Inc. (VCYT)?
What is the 5-year average Enterprise Value for Veracyte, Inc. (VCYT)?
How does the current Enterprise Value for Veracyte, Inc. (VCYT) compare to its historical average?